Motif Bio’s (MTFB) antibiotic drug Iclaprim met the Phase 3 Revive-2 trial’s primary endpoints of non-inferiority against the current standard of care antibiotic, vancomycin in acute bacterial skin and skin structure infections (ABSSSI). The drug demonstrated a 78% clinical skin infection cure.
According to Motif Bio, Iclaprim was nearly identical compared to vancomycin. The firm observed, though, that within 48 to 72 hours, a greater than 20 percent reduction in legion area has occurred. The Revive-2 data demonstrated that 54.6% of patients receiving iclaprim had . . .